<Suppliers Price>

Imlunestrant

Names

[ CAS No. ]:
2408840-26-4

[ Name ]:
Imlunestrant

Biological Activity

[Description]:

Imlunestrant (LY3484356) is an orally active selective estrogen receptor (ER) degrader (SERD). Imlunestrant (LY3484356) could be used in the study for ER+, HER2-advanced breast cancer[1].

[Related Catalog]:

Signaling Pathways >> Others >> Estrogen Receptor/ERR
Research Areas >> Cancer

[In Vitro]

Imlunestrant (LY3484356) shows favorable efficacy and pharmacokinetic (PK) properties, including antitumor activity in ESR1 mutants[1]. Imlunestrant (LY3484356) is a potent degrader and selective pure antagonist of wild type and mutant ERα[2].

[References]

[1]. Komal L. Jhaveri, et al. A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study. 2021 ASCO Annual Meeting I.

[2]. Cristina Hernando, et al. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. Int. J. Mol. Sci. 2021, 22(15), 7812.

Chemical & Physical Properties

[ Molecular Formula ]:
C29H24F4N2O3

[ Molecular Weight ]:
524.51

Related Compounds